Clinical Trial Update: Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer. [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating a PD-L1 inhibitor in combination with metronomic vinorelbine, cyclophosphamide, and capecitabine, with or without radiotherap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Capecitabine (capecitabine)
• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Advanced Triple-negative Breast Cancer | Phase 2 | Status: RECRUITING